Prostate Tissue BioBank

Launched by ABRAMSON CANCER CENTER AT PENN MEDICINE · Oct 24, 2024

Keywords

ClinConnect Summary

The Prostate Tissue BioBank is a research study focused on understanding prostate cancer, especially in men who have inherited genetic mutations that may increase their risk. The study aims to collect prostate tissue samples and DNA from men who have these genetic mutations, as well as from men who do not have them, to compare how the disease develops and how well different treatments work. This research is particularly important because we know that a significant number of men with prostate cancer carry inherited gene mutations, which can affect their health.

To be eligible for this study, men aged 65 to 74 who have a confirmed genetic mutation related to prostate cancer can participate, as well as men who are undergoing prostate biopsies or surgeries for prostate cancer but do not have these mutations. Participants can expect to provide tissue samples and DNA, which will help researchers learn more about prostate cancer and potentially improve treatment options in the future. This study is currently recruiting participants, and it offers a chance to contribute to important research that could benefit many men facing prostate cancer.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• Carriers (Group 1):
• • 1. Confirmed pathogenic or likely pathogenic variant in a known prostate cancer risk gene.
• • 2. Patients undergoing prostate biopsies as a part of their prostate cancer screening OR biopsy or prostatectomy due to a diagnosis of prostate cancer
• Controls (Group 2):
• • 1. Patients undergoing prostate biopsies as a part of their prostate cancer screening OR biopsy or prostatectomy due to a diagnosis of prostate cancer
• Exclusion Criteria:
• • N/A